关键信息
-
基因名
RARRES1
- 应用
-
别名
RARRES1;PEIG1;TIG1;Retinoic acid receptor responder Protein 1
-
种属
Human
-
表达系统
E. coli
-
标签
N-terminal His Tag
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P49788
-
表达区间
43-294aa
-
氨基酸序列
PDDPGQPQDAGVPRRLLQ QAARAALHFF NFRSGSPSAL RVLAEVQEGR AWINPKEGCKVHVVFSTERY NPESLLQEGEGRLGKCSARVFFKNQKPRPTINVTCTRLIEKKKRQQEDYLLYKQMKQLKNPLEIVSIPDNHGHIDPSLRLIWDLAFLGSSSHYYLAQLTS VRQWKTNDDTYVMWEMTTOVIDFDYTVLLHELSTQEIIPC RIHLVWYPGK PLKVKYHCQE LQTPEEASGTEEGSAVVPTE LSNF
-
分子量
35 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
RARRES1, or Retinoic Acid Receptor Responder 1, is a protein that has garnered significant interest in cancer research due to its potential role as a tumor suppressor. Initially identified in studies examining the effects of retinoic acid on gene expression, RARRES1 has been implicated in various cellular processes, including cell proliferation, differentiation, and apoptosis. Its expression is often downregulated in several types of cancers, including breast, prostate, and colorectal cancers, suggesting that it may play a pivotal role in tumorigenesis. Furthermore, studies have shown that RARRES1 interacts with multiple signaling pathways, potentially influencing the tumor microenvironment and immune response. Research on RARRES1 recombinant protein has focused on understanding its functional mechanisms, interactions with other proteins, and its potential as a biomarker for cancer diagnosis and prognosis. Additionally, investigations into the therapeutic applications of RARRES1 are ongoing, exploring its capability to reverse malignant phenotypes and enhance the efficacy of existing cancer treatments. The growing body of evidence highlights RARRES1 not only as a significant player in cancer biology but also as a promising target for novel therapeutic strategies aimed at improving patient outcomes in oncology.
